Jasper Therapeutics (JSPR) Competitors

$21.33
-0.09 (-0.42%)
(As of 05/10/2024 ET)

JSPR vs. TNYA, DCGO, BDTX, OCGN, AURA, SLDB, SOPH, CRBU, MGTX, and REPL

Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Tenaya Therapeutics (TNYA), DocGo (DCGO), Black Diamond Therapeutics (BDTX), Ocugen (OCGN), Aura Biosciences (AURA), Solid Biosciences (SLDB), SOPHiA GENETICS (SOPH), Caribou Biosciences (CRBU), MeiraGTx (MGTX), and Replimune Group (REPL). These companies are all part of the "medical" sector.

Jasper Therapeutics vs.

Jasper Therapeutics (NASDAQ:JSPR) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.

Jasper Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/A-$64.46M-$6.20-3.44
Tenaya TherapeuticsN/AN/A-$124.08M-$1.67-2.51

Jasper Therapeutics' return on equity of -63.21% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A -63.21% -55.07%
Tenaya Therapeutics N/A -69.94%-59.80%

Jasper Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.61, indicating that its share price is 161% more volatile than the S&P 500.

79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 3.9% of Jasper Therapeutics shares are owned by insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Jasper Therapeutics presently has a consensus target price of $64.29, indicating a potential upside of 201.39%. Tenaya Therapeutics has a consensus target price of $15.40, indicating a potential upside of 266.67%. Given Tenaya Therapeutics' higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Jasper Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jasper Therapeutics
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tenaya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Jasper Therapeutics received 2 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. Likewise, 83.33% of users gave Jasper Therapeutics an outperform vote while only 74.19% of users gave Tenaya Therapeutics an outperform vote.

CompanyUnderperformOutperform
Jasper TherapeuticsOutperform Votes
25
83.33%
Underperform Votes
5
16.67%
Tenaya TherapeuticsOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

In the previous week, Jasper Therapeutics had 11 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 13 mentions for Jasper Therapeutics and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.45 beat Jasper Therapeutics' score of 0.79 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jasper Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tenaya Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Jasper Therapeutics and Tenaya Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPR vs. The Competition

MetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$321.32M$2.83B$5.12B$7.81B
Dividend YieldN/A2.23%38.15%3.92%
P/E Ratio-3.4413.28111.8716.04
Price / SalesN/A312.292,416.2074.58
Price / CashN/A160.7148.8335.50
Price / Book3.034.505.334.38
Net Income-$64.46M-$45.68M$106.58M$217.46M
7 Day Performance-13.01%-1.81%-0.89%-0.14%
1 Month Performance-23.05%-3.41%-1.39%0.05%
1 Year Performance35.86%5.10%4.69%9.69%

Jasper Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TNYA
Tenaya Therapeutics
2.6224 of 5 stars
$4.62
-1.3%
$15.40
+233.3%
-42.6%$362.76MN/A-2.77140Gap Up
DCGO
DocGo
4.3803 of 5 stars
$3.51
+3.5%
$10.58
+201.5%
-64.3%$365.64M$624.29M50.144,164Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
BDTX
Black Diamond Therapeutics
2.2532 of 5 stars
$6.59
+11.7%
$12.25
+85.9%
+218.2%$346.17MN/A-3.5154Upcoming Earnings
Short Interest ↑
Analyst Revision
News Coverage
High Trading Volume
OCGN
Ocugen
0.7366 of 5 stars
$1.32
-5.0%
$4.67
+253.5%
+127.0%$339.68M$6.04M-4.8965Upcoming Earnings
AURA
Aura Biosciences
1.4158 of 5 stars
$7.77
+1.6%
$21.00
+170.3%
-28.4%$384.85MN/A-4.0588Short Interest ↑
News Coverage
SLDB
Solid Biosciences
4.0581 of 5 stars
$10.23
+7.2%
$18.25
+78.4%
+61.3%$387.31M$8.09M-2.1188
SOPH
SOPHiA GENETICS
1.5728 of 5 stars
$5.08
+0.8%
$8.00
+57.5%
+1.3%$331.37M$62.37M-4.16430Gap Down
CRBU
Caribou Biosciences
1.7429 of 5 stars
$3.64
-1.4%
$22.50
+518.1%
-19.2%$328.77M$34.48M-2.51158Upcoming Earnings
Short Interest ↓
Analyst Revision
News Coverage
MGTX
MeiraGTx
3.9941 of 5 stars
$4.99
flat
$25.67
+414.4%
-13.0%$320.91M$14.02M-3.39419News Coverage
REPL
Replimune Group
4.4003 of 5 stars
$6.56
+1.2%
$37.67
+474.2%
-65.8%$402.72MN/A-2.08284Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:JSPR) was last updated on 5/12/2024 by MarketBeat.com Staff

From Our Partners